• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13D/A filed by Ainos Inc. (Amendment)

    8/15/23 5:30:23 PM ET
    $AIMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AIMD alert in real time by email
    SC 13D/A 1 aimd_sc13da.htm SC 13D/A aimd_sc13da.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

    ______________

     

    SCHEDULE 13D

     

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)*

     

    Ainos, Inc.

    (Name of Issuer)

      

    Common Stock, $0.01 par value

    (Title of Class of Securities)

     

    00902F 204

    (CUSIP Number)

     

    Chun-Hsien Tsai

    Chief Executive Officer

    Ainos, Inc.

    14F., No. 61, Sec. 4, New Taipei Boulevard, Xinzhuang District

    New Taipei City 242, Taiwan F5

    886-37-581999

     

     (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     

    August 11, 2023

    (Date of Event Which Requires Filing of This Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the following box. 

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

    CUSIP No.

    00902F 204

     

     

    1

    NAME OF REPORTING PERSON:

     

    Ainos Inc.

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS):

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY:

     

    4

    SOURCE OF FUNDS (SEE INSTRUCTIONS):

     

    OO

    5

    CHECK IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) OR 2(e):

    ☐

    6

    CITIZENSHIP OR PLACE OF ORGANIZATION:

    Cayman Islands

      

    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH

    7

    SOLE VOTING POWER:

     

    12,281,601

    8

    SHARED VOTING POWER:

     

    12,947,011

     

    9

    SOLE DISPOSITIVE POWER:

     

    12,281,601

    10

    SHARED DISPOSITIVE POWER:

     

    12,947,011

      

    11

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON:

     

    12,947,0111

    12

    CHECK IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS):

     

    ☐

    13

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11):

     

    63.80%2

    14

    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS):

     

    CO

    _______________________________ 

    1 Represents beneficial ownership of 12,947,011 Common Shares, $0.01 par value (the “Common Shares”), of Ainos, Inc., a Texas corporation (the “Issuer”) consisting of the following: (i) 12,281,601 shares owned directly by Ainos Inc., a Cayman company (“Ainos KY”); and (ii) 665,410 shares pursuant to a Voting Agreement dated December 9, 2021 by and among the Issuer, Ainos Inc., Stephen T. Chen, Virginia M. Chen, Stephen T. Chen and Virginia M. Chen as trustees of the Stephen T. Chen and Virginia M. Chen Living Trust, dated April 12, 2018 (collectively the “Chen Group”), and Hung Lan Lee (the “Lee”) (the “Voting Agreement”).

    2 The percentage set forth in Row 13 of this Cover Page is calculated based on 20,292,624 Common Shares outstanding, as set forth in the Issuer’s Form 10-Q filed with the Securities and Exchange Commission on August 11, 2023 (the “Form 10-Q”), following a 15-to-1 reverse stock split effective as of August 8, 2022.

     

     
    2

     

     

    Schedule 13D

     

    Item 1. Security and Issuer

     

    This statement relates to the shares of common stock (“Common Stock”) of Ainos, Inc., a Texas corporation (the “Issuer”), the principal executive offices of which are located at 8880 Rio San Diego Drive, Suite 800, San Diego, CA 92108.

     

    Item 2. Identity and Background

     

    (a-b) This Schedule is being filed by Ainos Inc., a Cayman Islands corporation (“Ainos KY”). The principal business and office address of Ainos KY is P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands.

     

    Ainos KY is controlled by Taiwan Carbon Nano Technology Corporation, a Taiwanese corporation (“TCNT” and together with the Issuer, the “Parties”). The principal business and office address of TCNT is 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C.).

     

    (c) The principal business of Ainos KY is a holding company of the Issuer’s securities. The principal business of TCNT is the development of advanced materials for industrial and medical device applications.

     

    (d-e) During the last five years, the Parties, and their respective executive officers and directors, as applicable, have not (i) been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors) or (ii) been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.

     

    Item 3. Source and Amount of Funds or Other Consideration

     

    The information requested by this Item 3 is incorporated herein by reference to Item 5 hereof.

     

    Item 4. Purpose of Transaction

     

    The Parties acquired the Common Stock in the Issuer for investment purposes.

     

    Except as disclosed herein, each of the Parties has no plans which relate to or would result in an event described in subparagraphs (a) through (j) of Item 4 of Schedule 13D. However, each of the Parties may, from time to time, engage in discussions, whether initiated by the Parties or another party, concerning proposals for transactions or other arrangements that may relate to or, if consummated, result in an event described in Item 4 of Schedule 13D. Each of the Parties may review and evaluate their respective investments in the Issuer at any time, whether in light of the discussions described in the immediately preceding sentence or otherwise, which may give rise to plans or proposals that, if consummated, would result in one or more of the events described in Item 4 of Schedule 13D. Any such discussion or actions may consider various factors, including, without limitation, the Issuer’s business prospects and other developments concerning the Issuer, alternative investment opportunities, general economic conditions, financial and stock market conditions and any other facts and circumstances that may become known to the Parties regarding or related to the matters described in this Schedule 13D.

     

    Item 5. Interest in Securities of the Issuer

     

    (a-b) The information requested by these paragraphs is incorporated herein by reference to the cover pages to this Amendment No. 4 to Schedule 13D.

     

     
    3

     

     

    (c) Since the most recent filing of Amendment No. 3 to Schedule 13D on September 2, 2022, the following sales of Common Stock of the Issuer occurred:

     

     

    (i)

    On April 19, 2023, Ainos KY sold a total of 1,044,481 of Common Stock including 400,000 shares at $0.75 per share and 644,481 shares at $0.70 per share under a private sale.

     

     

     

     

    (ii)

    On April 19, 2023, pursuant to that certain Share Transfer Agreement and Release and Settlement Agreement, dated respectively January 27, 2023 (the “Chen Agreements”), Chen transferred 75,555 of Common Stock at $0.1875 per share to Hui Yuan, individually and as designee of Best Dynasty Investment Limited, a Hong Kong company.

     

     

     

     

    (iii)

    On or about May 2, 2023, pursuant to the Chen Agreements, Chen transferred at total of 44,444 of Common Stock at $0.1875 per share including 22,222 shares to Tak Wing Oswald Chan and 22,222 shares to See Yan Nick Lock.

     

    (d) No other person is known to the Parties to have the right to receive or the power to direct the receipt of dividends from, or proceeds from the sale of, the Shares.

     

    (e) Not applicable.

     

    Item 6.  Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer

     

    The information set forth in Item 5 of this Schedule 13D is hereby incorporated by reference into this Item 6, as applicable.

     

    Pursuant to the Voting Agreement, the Chen Group and Lee have agreed to vote all of their shares subject to the Voting Agreement as determined at the sole discretion of Ainos KY. The Chen Group and Lee each appointed the President of Ainos KY as their proxies and granted a power of attorney with full power of substitution in connection therewith. The Voting Agreement grants the Chen Group and Lee the authority to sell or transfer 25% of their respective shares in private transactions (including sales, gifts, or any other transfers) annually. The Voting Agreement may only be amended or terminated (i) by a written instrument executed by the parties subject to the Voting Agreement; (ii) when Ainos KY holds less than 10% beneficial ownership in the Common Shares of the Issuer; or (iii) when Ainos KY holds less than 10% voting interest in the Issuer.

     

    Other than the foregoing agreements and arrangements, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among Ainos KY or the Parties and any other person with respect to any securities of the Issuer, including, but not limited to transfer or voting of any of the securities, finder’s fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies.

     

    Item 7.  Material to be Filed as Exhibits

     

     EXHIBIT INDEX

     

     

    INCORPORATED BY REFERENCE

    EXHIBIT NUMBER

    DESCRIPTION

    FILED WITH THIS SCHEDULE 13D

    FILING DATE WITH SEC

    FORM

    EXH #

    HYPERLINK TO

    FILINGS

    1

    Voting Agreement

    09/02/2022

    13D/A

    1

    Voting Agreement

     

     
    4

     

     

    SIGNATURE

     

            After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: August 15, 2023

    By:

    /s/ Chun-Hsien Tsai

     

     

     

    Director and CEO of

    Ainos Inc., a Cayman Islands corporation

     

     

     
    5

     

     

    SCHEDULE A

    Officers and Directors of Ainos KY

     

    Note 1: The address of each individual is c/o Ainos, Inc., P. O. Box 31119 Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1 - 1205 Cayman Islands and each individual is a citizen of Taiwan except for Mr. Yukio Sakamoto, who is a citizen of Japan.

     

    Note 2:  Chun-Hsien Tsai’s beneficial ownership include 363,098 (Direct) shares and 71,657 (Indirect) shares owned by his wife, Ting Chuan Lee, a director of the Issuer.

     

    Chun-Hsien Tsai is also Chairman, President and CEO of the Issuer. Chun-Jung Tsai is also a director of the Issuer.

     

    Name

    Principal Occupation

    (and name/address of employer

    if not one of the entities listed on this Schedule)

    Principal Business Address

    Interest in Issuer

    (in shares of Common Stock)

    Hung-Szu Tung

    Director

    See Note 1.

    None

    Chun-Hsien Tsai

    Director & CEO

    See Note 1.

    434,755 2

    Chun-Jung Tsai

    Director

    See Note 1.

    19,432

    Yukio Sakamoto

    Director

    See Note 1.

    None

    Chih-Heng Lu

    Director

    See Note 1.

    103,100

     

     
    6

     

     

    SCHEDULE B

    Officers and Directors of TCNT

     

    Note 1: The address of each individual is c/o 10F-2, No. 66, Shengyi 5th Rd., Zhubei City, Hsinchu County 30261, Taiwan (R.O.C.) and each individual is a citizen of Taiwan.

     

    Note 2:  The combined beneficial ownership of Chun-Hsien Tsai and Ting Chuan Lee totals 434,755 shares.  Chun-Hsien Tsai directly owns 363,098 shares and his wife, Ting Chuang Lee directly owns 71,657 shares.

     

    Chun-Hsien Tsai is also Chairman, President and CEO of the Issuer. Chun-Jung Tsai, Ting-Chuan Lee and Chung Yi-Tsai are also directors of the Issuer.

     

    Name

    Principal Occupation

    (and name/address of employer

    if not one of the entities listed on this Schedule)

    Principal Business Address

    Interest in Issuer

    (in shares of Common Stock)

    Ting-Chuan Lee

    Director

    See Note 1.

    71,6572

    Chung Yi-Tsai

    Director

    See Note 1.

    7,333

    Chun-Hsien Tsai

    Chairman & CEO

    See Note 1.

    363,0982

    Chun-Jung Tsai

    Director

    See Note 1.

    19,432

    Ching-Ho Tsai

    Director

    See Note 1.

    None

    A-Wen Tsai Huang

    Supervisor

    See Note 1.

    None

      

     
    7
     

    Get the next $AIMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AIMD

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $AIMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Tsai Chun-Jung was granted 900,000 shares, increasing direct ownership by 170% to 1,427,900 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:35 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Director Lee Ting-Chuan was granted 900,000 shares, increasing direct ownership by 169% to 1,431,432 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:38 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CEO, PRESIDENT, CHAIRMAN Tsai Chun-Hsien was granted 900,000 shares, increasing direct ownership by 120% to 1,651,862 units (SEC Form 4)

      4 - Ainos, Inc. (0001014763) (Issuer)

      4/9/25 4:15:36 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Ainos Inc.

      SC 13D/A - Ainos, Inc. (0001014763) (Subject)

      11/27/24 6:08:44 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13D filed by Ainos Inc.

      SC 13D - Ainos, Inc. (0001014763) (Subject)

      8/21/24 8:22:28 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Ainos Inc.

      SC 13D/A - Ainos, Inc. (0001014763) (Subject)

      8/20/24 4:05:21 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Water Tower Research Spotlights Ainos' AI Nose Programs and Strategic Milestones for 2025

      Report highlights greater visibility in AI Nose developments, including robotics, smart manufacturing, elderly care monitoring, and women's health testing SAN DIEGO, CA / ACCESS Newswire / January 21, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos" or the "Company"), a pioneer of digiting scent and low-dose interferon therapeutics, today announced that Water Tower Research ("WTR") has published a report projecting increased visibility for the Company's transformative AI Nose programs. The report emphasizes anticipated progress for AI Nose across multiple sectors, including robotics, smart manufacturing, elderly care, and women's health.Key Highlights from the Report:AI Nose Technolog

      1/21/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Granted 180-Day Extension by Nasdaq to Regain Compliance With Minimum Bid Price Rule

      SAN DIEGO, CA / ACCESS Newswire / January 17, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), today announced that it had received written notification (the "Written Notification") from the Listing Qualifications Department of the Nasdaq Stock Market LLC ("Nasdaq") that the Company is eligible for a 180-day extension to regain compliance with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule").As previously reported, on July 15, 2024, the Company received a deficiency letter from the Nasdaq notifying the Company that, for the last 30 consecutive business days, the closing bid price for the Company's common stock has been below

      1/17/25 9:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

      Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

      1/13/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Financials

    Live finance-specific insights

    See more
    • Ainos Reports Third Quarter 2024 Financial Results

      Secured multi-regional patent assets, strengthening Ainos' AI Nose technology.Expanded VELDONA® patent portfolio with a new invention patent for treatments and preventions for coronavirus infections.Progressed clinical trials for VELDONA®, including new studies on Sjögren's syndrome and HIV-related oral warts. SAN DIEGO, CA / ACCESSWIRE / November 6, 2024 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW) ("Ainos", or the "Company"), an innovative healthcare company focused on advanced AI-driven point-of-care testing ("POCT") and low-dose interferon therapeutics, today announced its financial results for the third quarter ended September 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, Preside

      11/6/24 4:30:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports Second Quarter 2024 Financial Results

      Enrolling first subject for FCGS clinical study marks a solid start in shifting animal health emphasis to drug developmentsRobust financial runway for over 12 months following the prepayment of a senior secured convertible noteSAN DIEGO, CA / ACCESSWIRE / August 5, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on novel AI-powered point-of-care testing ("POCT") and low-dose interferon therapeutics ("VELDONA®"), today announced its financial results for the second quarter ended June 30, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "We've made meaningful progress

      8/5/24 4:15:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Reports First Quarter 2024 Financial Results

      Strategic focus on VELDONA and AI-powered point-of-care testing continues during 2024US$9M growth capital secured in May strengthens financial position for executing growth strategy SAN DIEGO, CA / ACCESSWIRE / May 13, 2024 / Ainos, Inc. (NASDAQ:AIMD, AIMDW))) ("Ainos", or the "Company"), a diversified healthcare company focused on the development of novel point-of-care testing ("POCT"), low-dose interferon therapeutics, and synthetic RNA-driven preventative medicine, today announced its financial results for the first quarter ended March 31, 2024.Chun-Hsien (Eddy) Tsai, Chairman of the Board, President, and Chief Executive Officer of Ainos, commented, "In the first quarter, we successfully

      5/13/24 4:10:00 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    Leadership Updates

    Live Leadership Updates

    See more
    • Ainos Unveils AI Nose for Robotics: Invites Global Robotics Companies to Join Forces in Shaping the Future of Smell-Enabled Robots

      Ainos invites robotics and humanoid companies to join Ainos Alliance and digitize smell SAN DIEGO, CA / ACCESSWIRE / January 13, 2025 / Ainos, Inc. (NASDAQ:AIMD)(NASDAQ:AIMDW), a pioneer of digitizing scent, proudly announces its revolutionary AI Nose for robotics application and invites robotics companies worldwide to join Ainos Alliance. This technology aims to equip robots with the ability to "smell," filling a long-standing gap in sensory capabilities. Powered by advanced artificial intelligence (AI) and micro-electromechanical systems (MEMS) gas sensors, AI Nose redefines how robots interact with the world, enabling transformative applications across industrial, healthcare, and everyday

      1/13/25 10:00:00 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AIMD
    SEC Filings

    See more
    • SEC Form PRE 14C filed by Ainos Inc.

      PRE 14C - Ainos, Inc. (0001014763) (Filer)

      5/19/25 4:15:23 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Ainos Inc.

      10-Q - Ainos, Inc. (0001014763) (Filer)

      5/14/25 4:05:51 PM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Ainos Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Ainos, Inc. (0001014763) (Filer)

      5/12/25 9:01:07 AM ET
      $AIMD
      Biotechnology: Pharmaceutical Preparations
      Health Care